Baseline characteristics of patients enrolled in the study (n = 31)
| Characteristic . | All patients (n = 31) . |
|---|---|
| Age, median (IQR), y | 26 (24-33) |
| Age of gestation, median (IQR), wk | 24 (16-27) |
| 13-17 wk, n (%) | 11 (35.5) |
| 18-22 wk, n (%) | 5 (16.1) |
| 23-27 wk, n (%) | 8 (25.8) |
| 28-32 wk, n (%) | 4 (12.9) |
| ≥33 wk, n (%) | 3 (9.7) |
| Platelet count on enrollment, median (IQR), ×109/L | 10 (6-12) |
| Primigravida, n (%) | 29 (93.5) |
| Underlying disease, n (%) | |
| Hypertension | 3 (9.7) |
| Diabetes | 4 (12.9) |
| Diagnosis of ITP, n (%) | |
| Before pregnancy | 23 (74.2) |
| In pregnancy | 8 (25.8) |
| Prior therapies, n (%) | |
| Dex+PLT transfusion | 7 (22.6) |
| Pred+PLT transfusion | 8 (25.8) |
| IVIG+PLT transfusion | 9 (29.0) |
| Dex+IVIG+PLT transfusion | 2 (6.5) |
| Pred+IVIG+PLT transfusion | 4 (12.9) |
| Dex+Pred+IVIG+PLT transfusion | 1 (3.2) |
| Peak platelet count during previous treatments, n (%) | |
| <30 × 109/L | 31 (100) |
| ≥30 × 109/L | 0 (0) |
| Total amount of platelets transfused per patient (unit)*, median (IQR) | 10 (6-17) |
| Platelet transfusion refractoriness, n (%) | 31 (100) |
| Patients on stable dose (15-30 mg/d) of Pred upon enrollment, n (%) | 10 (32.3) |
| Characteristic . | All patients (n = 31) . |
|---|---|
| Age, median (IQR), y | 26 (24-33) |
| Age of gestation, median (IQR), wk | 24 (16-27) |
| 13-17 wk, n (%) | 11 (35.5) |
| 18-22 wk, n (%) | 5 (16.1) |
| 23-27 wk, n (%) | 8 (25.8) |
| 28-32 wk, n (%) | 4 (12.9) |
| ≥33 wk, n (%) | 3 (9.7) |
| Platelet count on enrollment, median (IQR), ×109/L | 10 (6-12) |
| Primigravida, n (%) | 29 (93.5) |
| Underlying disease, n (%) | |
| Hypertension | 3 (9.7) |
| Diabetes | 4 (12.9) |
| Diagnosis of ITP, n (%) | |
| Before pregnancy | 23 (74.2) |
| In pregnancy | 8 (25.8) |
| Prior therapies, n (%) | |
| Dex+PLT transfusion | 7 (22.6) |
| Pred+PLT transfusion | 8 (25.8) |
| IVIG+PLT transfusion | 9 (29.0) |
| Dex+IVIG+PLT transfusion | 2 (6.5) |
| Pred+IVIG+PLT transfusion | 4 (12.9) |
| Dex+Pred+IVIG+PLT transfusion | 1 (3.2) |
| Peak platelet count during previous treatments, n (%) | |
| <30 × 109/L | 31 (100) |
| ≥30 × 109/L | 0 (0) |
| Total amount of platelets transfused per patient (unit)*, median (IQR) | 10 (6-17) |
| Platelet transfusion refractoriness, n (%) | 31 (100) |
| Patients on stable dose (15-30 mg/d) of Pred upon enrollment, n (%) | 10 (32.3) |
Dex, dexamethasone; Pred, prednisone.
Apheresis platelet product: 2.5 ×1011/unit.